Table 3.

Prognostic accuracy of indicated prevention tests in clinical medicine

At-risk population	Outcome	Diagnostic test	Sensitivity (follow-up)	Specificity (follow-up)	AUC (follow-up)
Patients presenting for CHR evaluation	Psychosis	CHR interview	0.96 (2 yrs.)	0.47 (2 yrs.)	0.89 (2 yrs.)
Men at risk for prostate cancer	Prostate cancer	PSA (72,73)	0.69 (5 yrs.)	0.89 (5 yrs.)	0.88 (5 yrs.)
Men at risk for colorectal cancer	Colorectal cancer	Risk prediction model (74)	NA (5 yrs.)	NA (5 yrs.)	0.80 (5 yrs.)
Women at risk for colorectal cancer	Colorectal cancer	Risk prediction model (74)	NA (5 yrs.)	NA (5 yrs.)	0.73 (5 yrs.)
Patients with transient ischemic attack	Stroke	ABCD2 score (75,76)	0.57 (30 days)	0.32 (30 days)	0.72 (7 days)
Patients with stable coronary disease	Coronary event	Framingham risk score + number of diseased vessels (77)	NA (8.5 yrs.)	NA (8.5 yrs.)	0.67 (77) (8.5 yrs.)
Pre-diabetes	Diabetes	30-min plasma glucose (78)	0.91 (9 yrs.)	0.39 (9 yr.)	0.67 (9 yrs.)
Mild cognitive impairment	Alzheimer’s disease	ADAS-cog subscale (79)	0.62 (1 yr.)	0.73 (1 yr.)	0.67 (1 yr.)
Women at risk for breast cancer	ER-positive invasive breast cancer	Gail model (80)	0.50 (5 yrs.)	0.65 (5 yrs.)	0.60 (5 yrs.)

CHR – clinical high risk, AUC – area under the curve, PSA – prostate specific antigen, ER – estrogen receptor, NA – not available, ADAS-cog – Alzheimer Disease Assessment Scale-cognitive part